Singapore Markets open in 53 mins

Is MEDNAX (MD) a Profitable Stock for Value Investors Now?

Zacks Equity Research

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put MEDNAX, Inc. MD stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, MEDNAX has a trailing twelve months PE ratio of 7.17, as you can see in the chart below:

 

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 17.78. If we focus on the long-term PE trend, MEDNAX’s current PE level puts it below its midpoint over the past five years.

 

Further, the stock’s PE compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 20.51. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers. 

 

We should also point out that MEDNAX has a forward PE ratio (price relative to this year’s earnings) of just 6.38, so it is fair to say that a slightly more value-oriented path may be ahead for MEDNAX stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings. 

Right now, MEDNAX has a P/S ratio of about 0.51. This is lower than the S&P 500 average, which comes in at 3.14 right now.  Also, as we can see in the chart below, this is below the highs for this stock in particular over the past few years.

 

If anything, MD is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms. 

Broad Value Outlook

In aggregate, MEDNAX currently has a Zacks Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes MEDNAX a solid choice for value investors, and some of its other key metrics make this pretty clear too.   

For example, the PEG ratio for MEDNAX is just 0.75, a level that is far lower than the industry average of 1.06. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, its P/CF ratio comes in at 4.43, which is lower than the industry average of 4.97. Clearly, MD is a solid choice on the value front from multiple angles.

What About the Stock Overall?  

Though MEDNAX might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and a Momentum Score of F. This gives MD a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been disappointing. The current quarter has seen five estimates go lower in the past sixty days compared to one higher while the current year estimate has seen six downward revision compared to two upward in the same time period.     

This has had a negative impact on the consensus estimate though as the current quarter consensus estimate has declined by 3.2% in the past two months, while the current year estimate has inched down by 2.9%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Mednax, Inc Price and Consensus

 

Mednax, Inc Price and Consensus

Mednax, Inc price-consensus-chart | Mednax, Inc Quote

Despite the bearish analyst sentiments, the stock holds a Zacks Rank #3 (Hold). Thus, we are looking for in-line performance from the company in the near term.

Bottom Line 

MEDNAX is an inspired choice for value investors, as it is hard to beat its incredible line up of statistics on this front. In fact, over the past two years, the Zacks Medical – Hospital industry has clearly outperformed the market at large, as you can see below:

 

However, with a sluggish industry rank (among bottom 33% of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall.

So, value investors might want to wait for estimates, analyst sentiment and industry trends to turn around in this name first, but once that happens, this stock could be a compelling pick.

Legalizing THIS Could Be Even Bigger than Marijuana

Americans spend an estimated $150 billion in this industry every year… more than twice as much as they spend on marijuana.

Now that 8 states have fully-legalized it (with several more states following close behind), Zacks has identified 5 stocks that could soar in response to the powerful demand. One industry insider described the future as “mind-blowing” – and early investors can still get in ahead of the surge.

See these 5 “sin stocks” now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Mednax, Inc (MD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research